Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
To the Editor: In their Editorial accompanying
the report of our trial of aptiganel for acute ischemic stroke,1
Drs Becker and Tirschwell2 make a number
of important and valid points. However, several of their inferences about
our study were based on incomplete information and thus require clarification.
Goldstein LB, Albers GW. Patient Safety in Trials of Therapy for Acute Ischemic Stroke. JAMA. 2002;287(8):987. doi:10.1001/jama.287.8.983